In our preliminary experiments, we have discovered that the widely prescribed pain killer Celebrex is able to inhibit the growth of multiple myeloma (MM) cells in cell culture, as well as after implantation into experimental mice. Even more so, Celebrex was able to block the growth of several MM cell lines that otherwise were resistant to various commonly used chemotherapeutic drugs. We now propose to expand our preliminary findings by using appropriate preclinical animal models of MM and investigate the potential usefulness of Celebrex for the therapy if human patients with MM - in particular those where disease has become drug resistant.